Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -1.97 is 1183% below its 5-year average of 0.18, near the low end of its 5-year range (-6.51–17.41).
As of the fiscal period ended Friday, July 31, 2026. 155.54% below its 12-month average of 3.55.
Reported quarterly debt to equity ratio; no daily interpolation. Q1 FY2027 (2026-07-31): -1.97.
DEBT TO EQUITY RATIO
-1.97
DEBT TO EQUITY RATIO AVG TTM
3.55
DEBT TO EQUITY RATIO AVG 3Y
0.43
DEBT TO EQUITY RATIO AVG 5Y
0.18
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-155.54%
CURRENT VS 3Y AVG
-553.89%
CURRENT VS 5Y AVG
-1182.68%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 522 covered companies
CURRENT VS SECTOR MEDIAN
-1558.98%
vs the sector median at left
HeartSciences Inc.
Market Cap
$7.67M
Debt to Equity Ratio
-1.97
TTM Avg
3.55
3Y Avg
0.43
5Y Avg
0.18
Market Cap
$7.83M
Debt to Equity Ratio
0.00
TTM Avg
0.06
3Y Avg
0.06
5Y Avg
0.05
Market Cap
$7.84M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.01
5Y Avg
0.00
Market Cap
$7.95M
Debt to Equity Ratio
0.07
TTM Avg
0.26
3Y Avg
0.17
5Y Avg
0.14
Market Cap
$7.36M
Debt to Equity Ratio
0.00
TTM Avg
0.03
3Y Avg
0.05
5Y Avg
0.05
Market Cap
$7.05M
Debt to Equity Ratio
0.03
TTM Avg
0.02
3Y Avg
0.20
5Y Avg
0.20
Market Cap
$8.38M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| HeartSciences Inc. (HSCS) | $7.67M | -1.97 | 3.55 | 0.43 | 0.18 |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.83M | 0.00 | 0.06 | 0.06 | 0.05 |
| GT Biopharma, Inc. (GTBP)vs › | $7.84M | 0.00 | 0.00 | 0.01 | 0.00 |
| Longeveron Inc. (LGVN)vs › | $7.47M | 0.06 | 0.11 | 0.16 | 0.47 |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.95M | 0.07 | 0.26 | 0.17 | 0.14 |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.36M | 0.00 | 0.03 | 0.05 | 0.05 |
| KALA BIO, Inc. (KALA)vs › | $7.25M | 0.00 | 1.31 | 2.43 | 2.58 |
| Mangoceuticals, Inc. (MGRX)vs › | $7.05M | 0.03 | 0.02 | 0.20 | 0.20 |
| Aprea Therapeutics, Inc. (APRE)vs › | $8.38M | 0.00 | 0.00 | 0.00 | 0.00 |
| DataMEDS AI, Inc. (MEDS)vs › | $8.42M | N/A | 3.73 | 3.73 | 3.73 |
Debt/Equity
-1.97
Current Ratio
0.12
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-07-31 | -1.97 |
| 2026-04-30 | 17.41 |
| 2026-01-31 | 1.46 |
| 2025-10-31 | 0.21 |
| 2025-07-31 | 0.62 |
| 2025-04-30 | 14.55 |
| 2025-01-31 | 1.67 |
| 2024-10-31 | 0.72 |
| 2024-07-31 | 0.17 |
| 2024-04-30 | 0.14 |
| 2024-01-31 | 0.12 |
| 2023-10-31 | -1.21 |
| 2023-07-31 | -3.05 |
| 2023-04-30 | 6.79 |
| 2023-01-31 | -6.51 |
| 2022-10-31 | 1.58 |
| 2022-07-31 | 0.41 |
| 2022-04-30 | -1.02 |
| 2022-01-31 | 0.00 |
| 2021-10-31 | 0.00 |
| 2021-07-31 | 0.00 |
| 2021-04-30 | -1.61 |
